Treatment of schizoaffective disorder and schizophrenia with mood symptoms

American Journal of Psychiatry

Volumn 156, Issue 8, 1999, Pages 1138-1148

  Levinson, Douglas F ^a   Umapathy, C ^b   Musthaq, Mohamado ^b  

^a AUH EPPI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; RISPERIDONE; TRYPTOPHAN;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; HUMAN; MOOD; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 0032839766     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kraepelin E: Dementia Praecox and Paraphrenia (1919). Translated by Barclay RM; edited by Robertson GM. New York, Robert E Krieger, 1971
2. Kasanin J: The acute schizoaffective psychoses. Am J Psychiatry 1933; 90:97-126
3. Welner A, Croughan JL, Robins E: The group of schizoaffective and related psychoses - critique, record, follow-up, and family studies, I: a persistent enigma. Arch Gen Psychiatry 1974; 31:628-631
4. Abrams R, Taylor MA: Mania and schizo-affective disorder, manic type: a comparison. Am J Psychiatry 1976; 133:1445-1447
5. Tsuang MT, Dempsey GM: Long-term outcome of major psychoses, II: schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1979; 36:1302-1304
6. Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, Fieve RR: Toward the validation of RDC schizoaffective disorder. Arch Gen Psychiatry 1980; 37:804-810
7. Brockington IF, Wainwright S, Kendell RE: Manic patients with schizophrenic or paranoid symptoms. Psychol Med 1980; 10: 73-83
8. Himmelhoch JA, Fuchs CZ, May SJ, Symons BJ, Neil JF: When a schizoaffective diagnosis has meaning. J Nerv Ment Dis 1981; 169:277-282
9. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders, 3rd ed, updated. New York, New York State Psychiatric Institute, Biometrics Research, 1981
10. Baron M, Gruen R, Asnis L, Kane J: Schizoaffective illness, schizophrenia and affective disorders: morbidity risk and genetic transmission. Acta Psychiatr Scand 1982; 65:253-262
11. Kendler KS, Gruenberg AM, Tsuang MT: A DSM-III family study of the nonschizophrenic psychotic disorders. Am J Psychiatry 1986; 143:1098-1105
12. Maier W, Lichtermann D, Minges J, Hallmayer J, Heun R, Benkert O, Levinson DF: Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study. Arch Gen Psychiatry 1993; 50:871-883
13. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35: 773-782
14. Williams JBW, Gibbon M, First MB, Spitzer RL, Davies M, Borus J, Howes MJ, Kane J, Pope HG, Rounsaville B, Wittchen H-U: The Structured Clinical Interview for DSM-III-R (SCID), II: multisite test-retest reliability. Arch Gen Psychiatry 1992; 49:630-636
15. Faraone SV, Blehar M, Pepple J, Moldin SO, Norton J, Nurnberger JI, Malaspina D, Kaufmann CA, Reich T, Cloninger CR, DePaulo JR, Berg K, Gershon ES, Kirch DG, Tsuang MT: Diagnostic accuracy and confusability analyses: an application to the Diagnostic Interview for Genetic Studies. Psychol Med 1996; 26:401-410
16. Martin RL, Cloninger CR, Guze SB, Clayton PJ: Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985; 46:9-13
17. McGlashan TH, Carpenter WT Jr: Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33:231-239
18. Siris SG: Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991; 17:75-98
19. Gershon ES, DeLisi LE, Hamovit J, Nurnberger JI Jr, Maxwell ME, Schreiber J, Dauphinais D, Dingman CW II, Guroff JJ: A controlled family study of chronic psychoses. Arch Gen Psychiatry 1988; 45:328-337
20. Maj M: Lithium prophylaxis of schizoaffective disorders: a prospective study. J Affect Disord 1988; 14:129-135
21. Bouman TK, Kampen JGN, Ormel J, Slooff CJ: The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizoaffective disorders. J Affect Disord 1986; 11: 275-280
22. Mattes JA, Nayak D: Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 1984; 19:445-449
23. Brewerton TD, Reus VJ: Lithium carbonate and L-tryptophan in the treatment of bipolar and schizoaffective disorders. Am J Psychiatry 1983; 140:757-760
24. Goode DJ, Manning A: A comparison of bupropion alone and with haloperidol in schizoaffective disorder, depressed type. J Clin Psychiatry 1983; 44:253-255
25. Kufferle B, Lenz G: Classification and course of schizo-affective psychoses: follow-up of patients treated with lithium. Psychiatr Clin (Basel) 1983; 16:169-177
26. Carman JS, Bigelow LB, Wyatt RJ: Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981; 42:124-128
27. Biederman J, Lerner Y, Belmaker RH: Combination of lithium carbonate and haloperidol in schizoaffective disorder. Arch Gen Psychiatry 1979; 36:327-333
28. Brockington IF, Kendell RE, Kellett JM, Curry SH, Wainwright S: Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. Br J Psychiatry 1978; 133:162-168
29. Okuma T, Yamashita I, Takahashi R, Itoh H, Kurihara M, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K: Clinical efficacy of carbamazepine in affective, schizoaffective and schizophrenic disorders. Pharmacopsychiatry 1989; 22:47-53
30. Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K: A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80:250-259
31. Ries RK, Wilson L, Bokan JA, Chiles JA: ECT in medication-resistant schizoaffective disorder. Compr Psychiatry 1981; 22: 167-173
32. Müller-Siecheneder F, Müller MJ, Hillert A, Szegedi, A, Wetzel H, Benkert O: Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18: 111-120
33. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, Depreist M: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorders and psychotic mood disorders. J Clin Psychiatry 1995; 56:466-470
34. Banov MD, Zarate CA, Tohen M, Scialabba D, Wines JD, Kolbrener M, Kim J, Cole JO: Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55:295-300
35. Ceskova E, Svetska J: Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26:121-124
36. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O'Brien S: Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52:411-414
37. Naber D, Hippius H: The European experience with use of clozapine. Hosp Community Psychiatry 1990; 41:886-890
38. Tollefson GD, Sanger TM, Lu Y: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250-258
39. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546
40. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J: Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52:29-41
41. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA: Maintenance imipramine therapy for secondary depression in schizophrenia. Arch Gen Psychiatry 1994; 51:109-115
42. Dufresne RL, Valentino D, Kass DJ: Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmcol Bull 1993; 29:249-255
43. Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, Litle P, Schmidt R, Kimes I: Antidepressants in "depressed" schizophrenic inpatients: a controlled trial. Arch Gen Psychiatry 1989; 46:922-928
44. Dufresne RL, Kass DJ, Becker RE: Bupropion and thiothixene vs placebo and thiothixene in the treatment of depression in schizophrenia. Drug Dev Res 1988; 12:259-266
45. Lerner Y, Mintzer Y, Schestatzky M: Lithium combined with haloperidol in schizophrenic patients. Br J Psychiatry 1988; 153:359-362
46. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB: Adjunctive imipramine in the treatment of postpsychotic depression. Arch Gen Psychiatry 1987; 44:533-539
47. Becker RE: Implications of the efficacy of thiothixene and a chlorpromazine-imipramine combination for depression in schizophrenia. Am J Psychiatry 1983; 140:208-211
48. Johnson DAW: A double-blind trial of nortriptyline for depression in chronic schizophrenia. Br J Psychiatry 1981; 139:97-101
49. Kurland AA, Nagaraju A: Viloxazine and the depressed schizophrenic: methodological issues. J Clin Pharmacol 1981; 21:37-41
50. Waehrens J, Gerlach J: Antidepressant drugs in anergic schizophrenia. Acta Psychiatr Scand 1980; 61:438-444
51. Prusoff BA, Williams DH, Weissman MM, Astrachan BM: Treatment of secondary depression in schizophrenia. Arch Gen Psychiatry 1979; 36:569-575
52. Singh AN, Saxena B, Nelson HL: A controlled clinical study of trazodone in chronic schizophrenic patients with pronounced depressive symptomatology. Curr Ther Res 1978; 23:485-501
53. Hayes SG: Long-term use of valproate in primary psychiatric disorders. J Clin Psychiatry 1989; 50(March suppl):35-39
54. McElroy SL, Keck PE Jr, Pope HG Jr: Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7:16-24
55. Puzynski S, Klosiewicz L: Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders. Psychopharmacol Bull 1984; 20:151-159
56. Schaff MR, Fawcett J, Zajecka JM: Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993; 54:380-384
57. Chouinard G, Annable L, Serrano M, Albert JM, Charette R: Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. Arch Gen Psychiatry 1975; 32:1295-1307
58. Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152:183-190
59. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997; 154(April suppl)
60. Small JG, Kellams JJ, Milstein V, Moore J: A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132:1315-1317
61. Growe GA, Crayton JW, Klass DB, Evans H, Strizich M: Lithium in chronic schizophrenia. Am J Psychiatry 1979; 136: 454-455
62. Johnson G: Differential response to lithium carbonate in manic-depressive and schizoaffective disorders. Dis Nerv Syst 1970; 13:613-615
63. Prien RF, Cafe EM, Klett JC: A comparison of lithium carbonate and chlorpramazine in the treatment of excited schizoaffectives. Arch Gen Psychiatry 1972; 27:182-189
64. Keck PE Jr, McElroy SL, Strakowski SM: New developments in the pharmacologic treatment of schizoaffective disorder. J Clin Psychiatry 1996; 57(suppl 9):41-48